$6.75
1.20% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US55234L1052
Symbol
LYRA

Lyra Therapeutics Inc Stock price

$6.75
-1.96 22.50% 1M
-3.08 31.30% 6M
-3.57 34.59% YTD
-8.40 55.45% 1Y
-323.25 97.95% 3Y
-666.25 99.00% 5Y
-921.25 99.27% 10Y
-921.25 99.27% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.08 1.20%
ISIN
US55234L1052
Symbol
LYRA
Industry

Key metrics

Basic
Market capitalization
$10.7m
Enterprise Value
$-21.1m
Net debt
positive
Cash
$31.7m
Shares outstanding
1.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.0 | 14.7
EV/Sales
negative | negative
EV/FCF
0.4
P/B
2.8
Financial Health
Equity Ratio
17.5%
Return on Equity
-805.9%
ROCE
-100.7%
ROIC
-230.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.2m | $725.0k
EBITDA
$-44.7m | $-17.7m
EBIT
$-45.2m | $-37.5m
Net Income
$-79.5m | $-19.2m
Free Cash Flow
$-56.4m
Growth (TTM | estimate)
Revenue
-29.2% | -52.6%
EBITDA
38.9% | 70.6%
EBIT
38.4% | 38.2%
Net Income
-15.5% | 79.5%
Free Cash Flow
22.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,772.3% | -2,442.5%
EBIT
-3,811.4%
Net
-6,711.4% | -2,647.9%
Free Cash Flow
-4,759.3%
More
EPS
$-60.5
FCF per Share
$-42.7
Short interest
3.7%
Employees
30
Rev per Employee
$50.0k
Show more

Is Lyra Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Lyra Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Lyra Therapeutics Inc forecast:

6x Hold
67%
3x Sell
33%

Analyst Opinions

9 Analysts have issued a Lyra Therapeutics Inc forecast:

Hold
67%
Sell
33%

Financial data from Lyra Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.19 1.19
29% 29%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
19% 19%
1,340%
- Research and Development Expense 30 30
43% 43%
2,555%
-45 -45
39% 39%
-3,756%
- Depreciation and Amortization 0.46 0.46
254% 254%
39%
EBIT (Operating Income) EBIT -45 -45
38% 38%
-3,795%
Net Profit -80 -80
15% 15%
-6,683%

In millions USD.

Don't miss a Thing! We will send you all news about Lyra Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyra Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 7 hours ago
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) –
Neutral
GlobeNewsWire
about 2 months ago
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants
Neutral
Seeking Alpha
about 2 months ago
Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, strong supporting data, and a good explanation for the ENLIGHTEN-1 failure, I believe the market is underestimating the potential for NDA submission without the need of another phase 3. Assuming pos...
More Lyra Therapeutics Inc News

Company Profile

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Head office United States
CEO Maria Palasis
Employees 30
Founded 2005
Website lyratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today